Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first).
Coverage summary
| Indication | Coverage |
|---|---|
| Wegovy (weight loss) | No |
| Zepbound (weight loss) | No |
| Ozempic / Mounjaro (type 2 diabetes) | Yes |
| Compounded semaglutide / tirzepatide | No |
Prior-authorization criteria
These rules come from the state preferred drug list (PDL), the list of drugs Nebraska Medicaid has agreed to pay for.
| Criterion | Value |
|---|---|
| PA burden | Medium |
| BMI threshold (weight-loss path) | Not applicable (weight-loss path not covered) |
| Comorbidity required | No |
| Last PDL update reviewed | 2025-Q3 |
What this means in practice
Nebraska Heritage Health MCOs follow the state PDL exclusion of weight-loss GLP-1. Diabetes coverage with PA is standard.
Managed-care organizations in Nebraska
Nebraska Medicaid pays private health plans, called managed-care organizations or MCOs, to run its coverage. An MCO has to cover at least what the state list covers and can add rules of its own. Check your own plan's current rules before you send anything in.
- Nebraska Total Care (Centene)
- Healthy Blue Nebraska (Anthem)
- UnitedHealthcare Community Plan
Cash-pay alternatives if Medicaid does not cover you
If you end up paying cash, the GLP-1 cost guide has what each cash route costs, from the compounded floor to the manufacturer-direct brand prices. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. Manufacturer savings cards and patient-assistance programs are not routes here: federal law bars the cards for anyone on Medicaid, and the free-drug programs require being uninsured.
If a supply gap rather than cost is blocking your refill, the GLP-1 shortage tracker shows which formulations the FDA lists as in shortage now. And if you are 65 or older and also have Medicare, the senior GLP-1 hub lays out the Medicare coverage paths for dual-eligible patients.
5 GLP-1 clinical trials are recruiting in Nebraska, and a study supplies its own study medication. Every site is listed on GLP-1 clinical trials in Nebraska.
Take it to your prescriber: PA letter library
Nebraska has no weight-loss path to appeal into. If you have type 2 diabetes, prior authorization is the route, and the letter library has the template your prescriber signs.
We keep a PA letter library with templates for 13 health plans, Anthem BCBS, Kaiser, Humana, Tricare and FEHB among them, sorted by the 7 clinical pictures that qualify. Each one cites the plan's own policy document, the diagnosis codes it asks for and the clinical trial evidence behind them.
If you have type 2 diabetes plus kidney disease and heart disease, that combination is the strongest case for approval in any state, and the templates cite the three clinical trials behind it.
If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.
Nebraska Medicaid GLP-1 FAQ
Does Nebraska Medicaid cover Wegovy for weight loss?
Does Nebraska Medicaid cover Zepbound for weight loss?
Does Nebraska Medicaid cover Ozempic or Mounjaro for diabetes?
What if Nebraska Medicaid does not cover my GLP-1?
Other state Medicaid pages
See the full 51-state coverage table for the side-by-side view across every US state.
How we built this page
Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.
Last updated: 2026-08-28. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Nebraska Medicaid, email hello@glpchart.com with the details and we will check it.